GB1242211A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB1242211A
GB1242211A GB36270/67A GB3627067A GB1242211A GB 1242211 A GB1242211 A GB 1242211A GB 36270/67 A GB36270/67 A GB 36270/67A GB 3627067 A GB3627067 A GB 3627067A GB 1242211 A GB1242211 A GB 1242211A
Authority
GB
United Kingdom
Prior art keywords
medicament
particle size
carrier
powder
effective particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB36270/67A
Inventor
Stephen Raymond Gunning
Philip Saxton Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Pharmaceuticals Ltd
Original Assignee
Fisons Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Pharmaceuticals Ltd filed Critical Fisons Pharmaceuticals Ltd
Priority to GB36270/67A priority Critical patent/GB1242211A/en
Priority to IE163/73A priority patent/IE32872B1/en
Priority to IE898/68A priority patent/IE32343B1/en
Priority to FI682158A priority patent/FI48973C/en
Priority to US748937A priority patent/US3634582A/en
Priority to BE718846D priority patent/BE718846A/xx
Priority to CA026,437A priority patent/CA946280A/en
Priority to NL6811060.A priority patent/NL161984C/en
Priority to DE1792207A priority patent/DE1792207C3/en
Priority to DE19681792799 priority patent/DE1792799A1/en
Priority to NO03102/68A priority patent/NO128307B/no
Priority to SE6810634A priority patent/SE372420B/xx
Priority to DK380968AA priority patent/DK123276B/en
Priority to FR162134A priority patent/FR8142M/fr
Priority to FR163601A priority patent/FR1605538A/fr
Priority to JP2321371A priority patent/JPS5643448B1/ja
Priority to US158059A priority patent/US3860618A/en
Publication of GB1242211A publication Critical patent/GB1242211A/en
Priority to US05/401,251 priority patent/US3957965A/en
Priority to MY330/74A priority patent/MY7400330A/en
Priority to MY329/74A priority patent/MY7400329A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Abstract

1,242,211. Powder compositions for inhalation. FISONS PHARMACEUTICALS Ltd. 23 July, 1968 [8 Aug., 1967], No. 36270/67. Heading A5B. A pharmaceutical powder composition for inhalation comprises a mixture of a solid finely divided medicament having an effective particle size in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water-soluble carrier having an effective particle size in the range 30-80 microns. The composition is preferably substantially free of particles having effective particle sizes in the range 11-29 microns. The medicament may be diluted with a solid pharmaceutically acceptable watersoluble diluent of the same effective particle size. The diluent or carrier may be dextran, mannitol or lactose preferably crystalline lactose. The medicament may be an antianaphylactic agent such as sodium chromoglycate, a sympathomimetic amine such as isoprenaline or ephedrine, an antibiotic such as penicillin or tetracycline, a steroid, enzyme, vitamin, antihistamine or mucolytic such as N- acetyl cysteine. A preferred composition contains sodium chromoglycate and isoprenaline sulphate. The surface characteristics of the medicament or carrier particles may have been modified by crystallisations, spray drying, precipitation or by coating with a pharmaceutically acceptable material, e.g. stearic acid or polyvinyl pyrrolidone (which coating may give the medicament sustained release action). The powder may be contained in a capsule, e.g. of gelatin or plastic, which is pierced for administration. The powder may be administered as a dispersion in an air stream obtained by simultaneous rotation and vibration of the pierced capsule. The composiitons are prepared by mixing together, preferably in a stirred mixer, the medicament and carrier, which if necessary have been subjected to comminution and particle size classification prior to mixing.
GB36270/67A 1967-08-08 1967-08-08 Pharmaceutical composition Expired GB1242211A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition
IE163/73A IE32872B1 (en) 1967-08-08 1968-07-25 Drug for use in pharmaceutical composition
IE898/68A IE32343B1 (en) 1967-08-08 1968-07-25 Pharmaceutical composition
FI682158A FI48973C (en) 1967-08-08 1968-07-30 A method of making a readily fluidizable inhalant.
US748937A US3634582A (en) 1967-08-08 1968-07-31 Pharmaceutical compositions
BE718846D BE718846A (en) 1967-08-08 1968-07-31
CA026,437A CA946280A (en) 1967-08-08 1968-08-01 Inhalant powder compositions
NL6811060.A NL161984C (en) 1967-08-08 1968-08-02 METHOD FOR PREPARING A PHARMACEUTICAL POWDER-INHALED PREPARATION, AND CONTAINER CONTAINING SUCH A PREPARATION
DE19681792799 DE1792799A1 (en) 1967-08-08 1968-08-03 PHARMACEUTICAL PREPARATIONS
DE1792207A DE1792207C3 (en) 1967-08-08 1968-08-03 Powder preparation for inhalation
NO03102/68A NO128307B (en) 1967-08-08 1968-08-07
SE6810634A SE372420B (en) 1967-08-08 1968-08-07
DK380968AA DK123276B (en) 1967-08-08 1968-08-07 Process for the preparation of an easily fluidizable inhalant.
FR162134A FR8142M (en) 1967-08-08 1968-08-07
FR163601A FR1605538A (en) 1967-08-08 1968-08-21
JP2321371A JPS5643448B1 (en) 1967-08-08 1971-04-14
US158059A US3860618A (en) 1967-08-08 1971-06-29 Chromone
US05/401,251 US3957965A (en) 1967-08-08 1973-09-27 Sodium chromoglycate inhalation medicament
MY330/74A MY7400330A (en) 1967-08-08 1974-12-30 Pharmaceutical composition
MY329/74A MY7400329A (en) 1967-08-08 1974-12-30 Drug for use in pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GB1242211A true GB1242211A (en) 1971-08-11

Family

ID=10386572

Family Applications (1)

Application Number Title Priority Date Filing Date
GB36270/67A Expired GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Country Status (14)

Country Link
US (1) US3634582A (en)
JP (1) JPS5643448B1 (en)
BE (1) BE718846A (en)
CA (1) CA946280A (en)
DE (2) DE1792207C3 (en)
DK (1) DK123276B (en)
FI (1) FI48973C (en)
FR (2) FR8142M (en)
GB (1) GB1242211A (en)
IE (1) IE32343B1 (en)
MY (2) MY7400329A (en)
NL (1) NL161984C (en)
NO (1) NO128307B (en)
SE (1) SE372420B (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2229981A1 (en) * 1971-06-22 1972-12-28 Fisons Ltd , London Pharmaceutical powder preparations
FR2481601A1 (en) * 1980-04-30 1981-11-06 Fisons Ltd PHARMACEUTICAL MIXTURE OF 1,3-BIS- (2-CARBOXYCHROMONE-5-YL-OXY) -PROPANE-2-OL, OR ONE OF ITS SALTS, AND AT LEAST ONE BRONCHODILATOR
US4515805A (en) * 1980-11-05 1985-05-07 Fisons Plc Soluble sodium cromoglycate compositions
US5551489A (en) * 1993-10-01 1996-09-03 Astra Aktiebolag Agglomeration of finely divided powders
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
US6183782B1 (en) 1994-03-15 2001-02-06 Glaxo Group Limited Inhalation composition containing lactose pellets
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US6371171B1 (en) 1993-10-01 2002-04-16 Astra Aktiebolag Agglomeration of finely divided powders
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6884794B2 (en) 2000-04-17 2005-04-26 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US7399528B2 (en) 1999-07-16 2008-07-15 Chiesi Farmaceutici S.P.A. Powder particles with smooth surface for use in inhalation therapy
US7541022B2 (en) 2000-04-17 2009-06-02 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
US8236979B2 (en) 2008-07-24 2012-08-07 American Air Liquide, Inc. Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
WO2013104892A1 (en) 2012-01-13 2013-07-18 Hovione Inter Limited Application of high dose compounds via inhalation
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
US9987229B2 (en) 2003-09-02 2018-06-05 Norton Healthcare Ltd. Process for preparing a medicament
WO2020031119A1 (en) 2018-08-07 2020-02-13 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP4316473A2 (en) 2013-03-28 2024-02-07 Vectura Limited Use of stearate in an inhalable formulation

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787100A (en) * 1971-08-06 1973-02-02 Beecham Group Ltd COMPOSITION FOR THE TREATMENT OF ASTHMA
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (en) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Use of corticosteroid active ingredients for inhalation therapy
DE2535258C2 (en) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalable drug in pellet form
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
JP2770970B2 (en) * 1987-04-09 1998-07-02 フアイソンズ・ピーエルシー Pharmaceutical composition containing pentamidine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
NL9301851A (en) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablation catheter.
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
KR100467058B1 (en) * 1997-05-27 2005-01-24 디렉트-할러 아/에스 Inhaler for powdered medicaments
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
CZ2001584A3 (en) * 1998-08-18 2002-06-12 The Regents Of The University Of California Prevention of phlegm formation in air passages by administering EGF-R antagonists
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
BR0107304A (en) * 2000-10-12 2002-08-13 Boehringer Ingelheim Pharma Inhalation powder containing tiotropium
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (en) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
EP1487417A4 (en) * 2001-09-17 2010-03-17 Glaxo Group Ltd Dry powder medicament formulations
MXPA04004730A (en) * 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (en) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
JP2006516531A (en) * 2002-08-21 2006-07-06 ノートン ヘルスケアー リミテッド Inhalation composition
DE10255387A1 (en) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New tiotropium-containing powder formulation for inhalation
DE10317461A1 (en) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
DE10338399A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
DE10338407A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
PE20050489A1 (en) 2003-11-04 2005-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
DE102004048389A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modification of surfaces of lactose as adjuvant for use with powder inhalants
DE102004048390A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New powder inhalants based on modified lactose mixtures as adjuvant
EP1848444B1 (en) * 2005-02-10 2016-11-09 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3054948B1 (en) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN110305095A (en) * 2013-10-22 2019-10-08 综合医院公司 Cromoglycic acid derivative and the correlation technique of imaging and treatment
PL3125875T3 (en) 2014-04-04 2023-11-20 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
JP6679584B2 (en) 2014-10-07 2020-04-15 エイアイ・セラピューティクス・インコーポレーテッド Inhalable rapamycin formulations for treating pulmonary hypertension
AU2017321782B2 (en) 2016-08-31 2022-03-10 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MX2019014671A (en) * 2017-06-28 2020-02-07 Philip Morris Products Sa Container with particles for use with inhaler.
MX2020000577A (en) 2017-07-20 2020-09-10 Aztherapies Inc Powdered formulations of cromolyn sodium and ibuprofen.
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation Powdered formulations of cromolyn sodium and ?-lactose
US20230310363A1 (en) 2020-08-28 2023-10-05 Universität Linz Use of leoligin in the prevention of tissue damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (en) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri TRANSPORTABLE GARDEN SWIMMING POOL OR POOL WITH WALLS MADE OF PLASTIC FOIL.
FR1489749A (en) * 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Process for the preparation of bis-chromonyl compounds and their derivatives

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2229981A1 (en) * 1971-06-22 1972-12-28 Fisons Ltd , London Pharmaceutical powder preparations
FR2481601A1 (en) * 1980-04-30 1981-11-06 Fisons Ltd PHARMACEUTICAL MIXTURE OF 1,3-BIS- (2-CARBOXYCHROMONE-5-YL-OXY) -PROPANE-2-OL, OR ONE OF ITS SALTS, AND AT LEAST ONE BRONCHODILATOR
US4515805A (en) * 1980-11-05 1985-05-07 Fisons Plc Soluble sodium cromoglycate compositions
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6371171B1 (en) 1993-10-01 2002-04-16 Astra Aktiebolag Agglomeration of finely divided powders
US5551489A (en) * 1993-10-01 1996-09-03 Astra Aktiebolag Agglomeration of finely divided powders
US8137657B2 (en) 1993-10-26 2012-03-20 Vectura Limited Carrier particles for use in dry powder inhalers
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US6582678B2 (en) 1993-10-26 2003-06-24 Vectura Limited Carrier particles for use in dry powder inhalers
US6955824B1 (en) 1994-03-15 2005-10-18 Glaxo Group Limited Inhalation composition containing lactose pellets
US6183782B1 (en) 1994-03-15 2001-02-06 Glaxo Group Limited Inhalation composition containing lactose pellets
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
EP2213279A3 (en) * 1995-01-31 2010-10-13 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US8920781B2 (en) 1995-01-31 2014-12-30 Vectura Limited Carrier particles for use in dry powder inhalers
US7011818B2 (en) 1995-01-31 2006-03-14 Vectura Limited Carrier particles for use in dry powder inhalers
EP1666023A2 (en) 1995-01-31 2006-06-07 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
EP2258342A3 (en) * 1995-01-31 2014-01-08 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
EP1666023B1 (en) * 1995-01-31 2011-10-05 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US7718163B2 (en) 1995-01-31 2010-05-18 Vectura Limited (01696917) Carrier particles for use in dry powder inhalers
US7399528B2 (en) 1999-07-16 2008-07-15 Chiesi Farmaceutici S.P.A. Powder particles with smooth surface for use in inhalation therapy
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
EP1719505A2 (en) 2000-04-17 2006-11-08 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations for dry powder inhalers in the form of hard pellets
EP2272508A2 (en) 2000-04-17 2011-01-12 Vectura Limited Pharmaceutical Formulations for Dry Powder Inhalers
US7541022B2 (en) 2000-04-17 2009-06-02 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US7223748B2 (en) 2000-04-17 2007-05-29 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US6884794B2 (en) 2000-04-17 2005-04-26 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US8871274B2 (en) 2000-04-17 2014-10-28 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US9566239B2 (en) 2000-04-17 2017-02-14 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US9987229B2 (en) 2003-09-02 2018-06-05 Norton Healthcare Ltd. Process for preparing a medicament
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
US8236979B2 (en) 2008-07-24 2012-08-07 American Air Liquide, Inc. Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2013104892A1 (en) 2012-01-13 2013-07-18 Hovione Inter Limited Application of high dose compounds via inhalation
EP4316473A2 (en) 2013-03-28 2024-02-07 Vectura Limited Use of stearate in an inhalable formulation
WO2020031119A1 (en) 2018-08-07 2020-02-13 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
EP3910324A1 (en) 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders

Also Published As

Publication number Publication date
MY7400329A (en) 1974-12-31
DE1792207B2 (en) 1977-10-13
BE718846A (en) 1969-01-31
NL161984C (en) 1980-04-15
DE1792207A1 (en) 1971-11-04
NL161984B (en) 1979-11-15
FI48973C (en) 1975-03-10
DK123276B (en) 1972-06-05
MY7400330A (en) 1974-12-31
IE32343L (en) 1969-02-08
FI48973B (en) 1974-12-02
FR8142M (en) 1970-08-17
JPS5643448B1 (en) 1981-10-13
FR1605538A (en) 1979-02-23
SE372420B (en) 1974-12-23
NO128307B (en) 1973-10-29
DE1792799A1 (en) 1977-08-11
DE1792207C3 (en) 1978-06-29
US3634582A (en) 1972-01-11
IE32343B1 (en) 1973-06-27
NL6811060A (en) 1969-02-11
CA946280A (en) 1974-04-30

Similar Documents

Publication Publication Date Title
GB1242211A (en) Pharmaceutical composition
JP2974409B2 (en) Particulate drug composition
EP0322137B1 (en) Spray dried ibuprofen
US3882228A (en) Analgesic formulations
CA2124568C (en) Method for producing microgranulated particle
GB1381872A (en) Pharmaceutical compositions for inhalation
MX9404762A (en) COMPOSITIONS FOR INHALATION AND PROCESS FOR ITS PREPARATION.
US4757090A (en) Direct tableting acetaminophen compositions
US4661521A (en) Direct tableting acetaminophen compositions
CA2125685A1 (en) Powders for inhalation and process for preparing them
CA2430318A1 (en) Powder formulation and method for producing the same
EP1036562A1 (en) Soft-pellet drug and process for the preparation thereof
AU1434700A (en) Dry powder pharmaceutical formulation
GB934089A (en) Improvements in or relating to sustained release medicaments
KR20000070189A (en) New Formulation for Inhalation Having a Poured Bulk Density of from 0.28 to 0.38 g/㎖, Comprising Terbutaline Sulphate, a Process for Preparing the Formulation and the Use Thereof
JPH0399014A (en) Riboflavin granule containing no auxiliaries
JPS63112519A (en) Production of nifedipine preparation
JP5034226B2 (en) Solid formulation with stabilized ingredients
GB644081A (en) Improvements in pectin products and the process of making same
JPH0967247A (en) Production of medicinal preparation of uniformly fine particle
GB1511852A (en) Reconstitutable powders
GB1468815A (en) Pharmaceutical compositions
JPS6271552A (en) Fine granulation of organic compound
JPH02231419A (en) Manufacture of particle improved in fluidity, shelf stability, and pharmaceutical property, and drug containing said particle
ES413624A3 (en) A method for preparing a phymaceutical composition in easy fluidizable powder, specially intended for the treatment by inhalation of allergic diseases of the respiratory tract. (Machine-translation by Google Translate, not legally binding)